Abstract: Administration of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid is effective for treating a stomach or small intestine ulcer.

Abstract: The present invention relates to methods for treating or controlling schizophrenia in a mammal using compounds having the Formula (I), wherein M1 and M2 are defined in the application.

Abstract: The present invention relates to a method for the treatment and/or amelioration of urticaria, the method comprising the administration of a pharmaceutically active dose of a compound of formula I to a subject in need of such a treatment and/or amelioration.

Abstract: The present invention relates to methods of treating emesis by administering to the subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to methods of using thiazolidinedione analogues of formula I: for treating Alzheimer's disease The terms R1, R2 and R3 are herein defined.

Abstract: A method is provided for the prevention and treatment of patients having impaired gastro-intestinal tract function. The method comprises the steps of administering to a patient requiring same free amino acids including about 9.0% to about 17.0% glutamic acid.

Abstract: Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.

Abstract: The invention relates to a method and composition for treatment of oxidative stress resulting from hemodialysis treatment in patients suffering from chronic kidney failure or End-Stage Renal Disease by administration of cystine, cysteine or mixtures thereof.

Abstract: This invention discloses the use of compounds of the azetidinone family in treatment of cholesterol gallstone disease of the biliary tree in mammals. These drugs act by decreasing biliary cholesterol secretion, and at the same time increasing the biliary flow and the hepatic secretion of endogenous compounds (e.g. bile salts, phospholipids) into the bile, in turn, these endogenous compounds contribute to inhibiting precipitation and the formation of gallstones in the biliary tree.

Abstract: The invention provides a method for treating or ameliorating colon cancer in a mammal comprising administering to the mammal a therapeutically effective amount of one or more compounds selected from the group consisting of compounds of Formula (1), (2), and a pharmaceutically acceptable salt or metabolite thereof.

Abstract: A novel therapeutic and prophylactic agent for inflammatory bowel diseases and a method for treating inflammatory bowel diseases is provided. The agent comprises a 2-amino-1,3-propanediol derivative (e.g., 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol hydrochloride) represented by the chemical formula (1) or a pharmaceutically acceptable salt or hydrate thereof: The agent is useful in the treatment or prevention of Crohn's disease, Crohn's disease in large intestine, intestinal Behcet's disease, ulcerative colitis, bleeding rectal ulcer and pouchitis.

Abstract: This application relates to methods of treating and ameliorating fibrosis, such as fibrosis of the pancreas. In particular, the application relates to methods of using a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors) for the treatment of pancreatic fibrosis.

Abstract: A method for treating amyotrophic lateral sclerosis is disclosed wherein a compound having xanthine dehydrogenase inhibiting activity is administered.

Abstract: The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

Abstract: A method is disclosed wherein semapimod, and/or the mesylate salt thereof, is administered for the treatment of necrotizing enterocolitis.

Abstract: The present invention provides methods of treating diarrhea-associated irritable bowel syndrome (IBS-D) following rifaximin administration.

Abstract: A method of treating emesis with growth hormone secretagogues, particularly ipamorelin.

Abstract: The present invention relates to blocking salt taste using compounds of Formula I as defined herein.

Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.

Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.